BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCardia (NASDAQ:BCDA) will report 2025 financial results and provide a corporate update on a conference call on March 24, 2026 at 4:30 PM EDT. The event includes management remarks and a Q&A, with live webcast access and replay availability through June 24, 2026.
Registered participants receive dial-in details; domestic and international phone numbers and replay instructions are provided for listeners.
Key Figures
- Results period
- Year ended December 31, 2025
- Financial results to be discussed on the call
- Call date
- March 24, 2026
- Corporate update and 2025 results conference call
- Call time
- 4:30 PM EDT
- Scheduled start time for prepared remarks and Q&A
- U.S. dial-in
- 1-833-316-0559
- Phone access for U.S. participants not pre-registered
- International dial-in
- 1-412-317-5730
- Phone access for international participants
- Replay end date
- June 24, 2026
- Approximate end of webcast replay availability
- Replay dial-in (US/Canada)
- 1-855-669-9658
- Toll-free replay access for domestic/Canada listeners
- Replay access code
- 7756290
- Code required for telephonic replay
Previous Conferences,earnings Reports
-
Scheduled Q3 2025 corporate update and financial results conference call.
-
Announced Q2 2025 earnings conference call and corporate update timing.
-
Scheduled Q1 2025 corporate update and financial results call.
-
Outlined 2024 financial results release and accompanying conference call.
-
Announced Q3 2024 corporate update and financial results conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the year ended December 31, 2025 by conference call on Tuesday, March 24, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.
Participants can register for the conference by navigating to https://dpregister.com/sreg/10207584/1039b7a7360.
Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=5Vq7aAhd
A webcast replay of the call will be available approximately one hour after the end of the call through approximately June 24, 2026 at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will also be available and may be accessed by calling 1-855-669-9658 (toll free domestic/Canada), 1-412-317-0088 (international toll) by using access code 7756290.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. BioCardia also acts as a biotherapeutic delivery partner supporting therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information visit www.biocardia.com.
MEDIA CONTACT:
Miranda Peto, Investor Relations
mpeto@biocardia.com
(650) 226-0120
INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@biocardia.com
(650) 226-0120
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.